ANGIODYNAMICS INC — fact timeline

ANGIODYNAMICS INC reported third quarter of fiscal year 2026 ended February 28, 2026 results: revenue $78.4 million. Guidance raised.

“the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights Quarter Ended February 28, 2026 Pro Forma* YoY Growth Net Sales $78.4 million 8.9% Med Tech Net Sales $37.3 million 19.0% Med Device Net Sales $41.1 million 1.1% • GAAP gross margin of 52.9% • GAAP loss per share of $0.19 • Adjusted loss per share of $0.07”

ANGIODYNAMICS INC incurred revolving credit of $25 million secured revolving credit facility with JPMorgan Chase Bank, N.A. at Adjusted Term SOFR plus 2.00% or ABR plus 1.00% maturing May 28, 2027.

“The Credit Agreement provides for a $25 million secured revolving credit facility (the “ Revolving Facility ”) with a maturity date of May 28, 2027, which is subject to a borrowing base comprised of certain working capital assets of the Company. Additionally, until such time as the Company has demonstrated a fixed charge coverage ratio greater than 1:10 to 1.00, the Revolving Facility will be further reduced by $5,000,000 (such period, the “ Availability Block Period ”). To the extent requested by the Company, and subject to certain customary limitations, the lenders will make revolving loan advances to the Company and the issuing bank will issue letters of credit for the account of the Company, in each case in an aggregate amount not exceeding the availability under the Revolving Facility. Issuances of letters of credit under the Revolving Facility shall further be limited by an issuance cap, which as at the closing date is set at $2,000,000. The proceeds of the Revolving Facility”

ANGIODYNAMICS INC reported financial results for the fiscal third quarter ended February 29, 2024.

“On April 4, 2024, AngioDynamics issued a press release announcing financial results for the fiscal third quarter ended February 29, 2024.”

ANGIODYNAMICS INC entered into Settlement Agreement with Becton, Dickinson and Company, C.R. Bard, Inc. and Bard Peripheral Vascular Inc. valued at one-time lump sum payment to BD in the amount of $7 million, $3 million of which will be payable wit (effective 2024-03-31).

“On March 31, 2024, AngioDynamics and BD entered into a Settlement Agreement (the “Settlement Agreement”) to resolve the Actions.”

James Clemmer was appointed as Director at ANGIODYNAMICS INC.

“James Clemmer resigned from his position as a Class II director on the Board and was immediately re-appointed as a Class I director”

Jan Stern Reed was appointed as Chair of the Nominating, Compliance and Corporate Governance Committee at ANGIODYNAMICS INC.

“Jan Stern Reed as the new chair of the Nominating, Compliance and Corporate Governance Committee”

Wesley Johnson was appointed as Chair of the Audit Committee at ANGIODYNAMICS INC.

“the Board appointed Wesley Johnson as the new chair of the Audit Committee”

Dennis Meteny resigned as member of the Board of Directors at ANGIODYNAMICS INC.

“On January 16, 2024, Dennis Meteny announced his intention to retire and resign from his position as a member of the Board of Directors (the “Board”) of AngioDynamics, Inc. (“AngioDynamics” or the “Company”) and as a member of the Compensation Committee and chair of the Audit Committee, effective January 31, 2024.”

ANGIODYNAMICS INC reported second quarter of fiscal year 2024 ended November 30, 2023 results: revenue $ 79.1 million, net income net loss of $ 29.0 million, EPS loss per share of $0.72.

“Net sales for the second quarter of fiscal year 2024 were $ 79.1 million, an increase of 2.7% compared to the prior-year quarter. Foreign currency translation did not have a significant impact on the Company ' s net sales in the quarter. Med Tech net sales were $ 25.4 million, a 3.5 % increase from $24.5 million in the prior- year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform. Year-over-year growth was driven by Auryon sales during the quarter of $11.4 million, which increased 12.9%, and AlphaVac sales of $1.9 million, which grew 17.9%. AngioVac sales were $5.4 million in the quarter, a decline of 10.8% from the second quarter of fiscal 2023. The Company completed enrollment of its APEX-AV trial subsequent to quarter end. Med Device net sales were $ 53.7 million, a 2.3% increase from sales of $52.5 in the prior-year period. U.S. net sales in the second quarter of fiscal 2024”

David D. Helsel resigned as Senior Vice President of Global Operations and R&D at ANGIODYNAMICS INC.

“On December 29, 2023, David D. Helsel, Senior Vice President of Global Operations and R&D, notified the Company of his intention to leave the Company, effective January 12, 2024, in order to pursue other opportunities.”

ANGIODYNAMICS INC shareholders approved Advisory vote on frequency of Say On Pay vote at the 2023-11-14 meeting.

“5. The proposal to approve, on an advisory basis the frequency of the Say On Pay vote was approved to take place annually based upon the following votes: Votes for 1 year 24,882,516 Votes for 2 years 5,024 Votes for 3 years 1,696,442 Abstentions 9,060 Broker non-votes 5,784,837”

ANGIODYNAMICS INC shareholders approved Approve amendments to the AngioDynamics, Inc. 2020 Equity Incentive Plan at the 2023-11-14 meeting.

“4. The proposal to approve amendments to the AngioDynamics, Inc. 2020 Equity Incentive Plan was approved based upon the following votes: Votes for approval 24,111,357 Votes against 2,461,478 Abstentions 20,207 Broker non-votes 5,784,837”

ANGIODYNAMICS INC shareholders approved Advisory approval of executive compensation (Say On Pay) at the 2023-11-14 meeting.

“3. The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers (“Say On Pay”) was approved based upon the following votes: Votes for approval 24,393,365 Votes against 2,193,446 Abstentions 6,231 Broker non-votes 5,784,837”

ANGIODYNAMICS INC shareholders approved Ratify appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-11-14 meeting.

“2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2024 was approved based upon the following votes: Votes for approval 32,364,352 Votes against 11,237 Abstentions 2,290 There were no broker non-votes for this item.”

ANGIODYNAMICS INC shareholders approved Election of Class II directors at the 2023-11-14 meeting.

“1. The nominees for election to the Board of Directors of AngioDynamics were elected, each as a Class II director to serve until the 2026 Annual Meeting of Shareholders of AngioDynamics and until their respective successors are duly elected and qualified, based upon the following votes: Nominee Votes For Withheld Broker Non-Votes Eileen O. Auen 23,553,074 3,039,968 5,784,837 James C. Clemmer 25,883,397 709,645 5,784,837 Howard W. Donnelly 24,605,006 1,988,036 5,784,837 Jan Stern Reed 24,900,465 1,692,577 5,784,837”

ANGIODYNAMICS INC reported the first quarter of fiscal year 2024, which ended August 31, 2023 results: revenue $78.7 million, net income $45.9 million, EPS $1.15. Guidance reaffirmed.

“795-1408 AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance Fiscal Year 2024 First Quarter Highlights • Net sales of $78.7 million as reported o Includes $0.7 million of Dialysis and BioSentry Biopsy Tract Sealant System sales o Net sales increased 5.7% on a pro-forma basis when excluding Dialysis and”

Lorinda Burgess was appointed as Class III Director at ANGIODYNAMICS INC.

“On July 19, 2023, the board of directors (the “Board”) of AngioDynamics, Inc. (“AngioDynamics”) approved an increase in the size of the Board to a total of nine directors and appointed Lorinda Burgess as a Class III director of AngioDynamics, effective immediately.”

ANGIODYNAMICS INC reported fiscal year ended May 31, 2023 results: revenue $338.8 million, EPS GAAP loss per share of $1.33. Guidance initiated.

“Full-Year 2023 Highlights • Net sales of $338.8 million increased 7.1% year over year • Gross margin declined 100 basis points year over year to 51.4% • GAAP loss per share of $1.33 , inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023 • Adjusted loss per share of $0.06”

ANGIODYNAMICS INC reported fiscal fourth quarter ended May 31, 2023 results: revenue $91.1 million, net income net loss of $21.5 million, EPS GAAP loss per share of $0.54. Guidance initiated.

“Fiscal Year 2023 Fourth Quarter Highlights • Net sales of $91.1 million increased 4.7% compared to the prior-year quarter o Med Tech net sales of $26.5 million increased 17.2% o Med Device net sales of $64.6 million increased 0.3% • Gross margin of 50.9% declined 250 basis points year over year • GAAP loss per share of $0.54, inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023 • Adjusted earnings per share of $0.02”

ANGIODYNAMICS INC completed a disposition involving Merit Medical Systems, Inc. for $100,000,000 in cash (closed 2023-06-08).

“to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy product of AngioDynamics (the “ Business ”) for a purchase price equal to $100,000,000 in cash, subject to the terms and conditions of the Asset Purchase Agreement (the “ Transaction ”). The Transaction was effective as of 12:01 a.m. mountain time on June 8, 2023”

ANGIODYNAMICS INC terminated Credit Agreement with lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger (effective 2022-06-08).

“On June 8, 2022, AngioDynamics used a portion of the consideration received in connection with the Transaction to repay all amounts owed under AngioDynamics’ existing Credit Agreement, dated as of August 30, 2022, with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger (the “ Credit Agreement ”), and as a result, the Credit Agreement was terminated.”

ANGIODYNAMICS INC entered into Asset Purchase Agreement with Merit Medical Systems, Inc. valued at $100,000,000 (effective 2023-06-08).

“On June 8, 2023, AngioDynamics, Inc., a Delaware corporation (“ AngioDynamics ” or the " Company "), entered into an asset purchase agreement (the “ Asset Purchase Agreement ”) with Merit Medical Systems, Inc., a Utah corporation (“ Merit ”), pursuant to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy product of AngioDynamics (the “ Business ”) for a purchase price equal to $100,000,000 in cash, subject to the terms and conditions of the Asset Purchase Agreement (the “ Transaction ”).”

ANGIODYNAMICS INC reported the third quarter of fiscal year 2023, which ended February 28, 2023 results: revenue $80.7 million, net income net loss of $9.5 million, or a loss per share of $0.24, EPS loss per share of $0.24. Guidance lowered.

“Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance Fiscal Year 2023 Third Quarter Highlights • Net sales of $80.7 million increased 9.1% compared to the prior-year quarter o Med Tech net sales of $22.9 million increased 16.6% o Med Device net sales of $57.8 million increased 6.4% • Gross margin of”

ANGIODYNAMICS INC reported fiscal year 2023 results: revenue $342 to $348 million, EPS adjusted earnings per share in the range of $0.01 to $0.06. Guidance reaffirmed.

“Management is reaffirming its previously issued fiscal year 2023 guidance. Management expects net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06 as it continues to invest in new product launches to drive future growth.”

ANGIODYNAMICS INC reported the six months ended November 30, 2022 results: revenue $167.0 million, net income net loss of $21.5 million, EPS loss of $0.55 per share.

“For the six months ended November 30, 2022: Net sales were $167.0 million, an increase of 7.5%, compared to $155.3 million for the same period a year ago. Med Tech net sales were $47.3 million, a 29.7% increase from the prior year period. Med Device net sales were $119.6 million, an increase of 0.7% from the prior year period. Gross margin increased 30 basis points to 52.3% from 52.0% a year ago. The Company’s net loss was $21.5 million, or a loss of $0.55 per share, compared to a net loss of $15.3 million, or a loss of $0.39 per share, a year ago. Excluding the items shown in the non-GAAP reconciliation table, below, adjusted net loss was $2.1 million, with adjusted loss per share of $0.05, compared to adjusted net loss and adjusted loss per share of $1.7 million, and $0.04, respectively, a year ago. Adjusted EBITDA, excluding the items shown in the reconciliation table below, was $10.4 million, compared to $8.0 million for the same period a year ago.”

ANGIODYNAMICS INC reported the fiscal second quarter ended November 30, 2022 results: revenue $85.4 million, net income net loss of $8.5 million, EPS loss per share of $0.21.

“Net sales for the second quarter of fiscal 2023 were $85.4 million, an increase of 9.1% compared to the prior-year quarter. Foreign currency translation did not have a significant impact on the Company ' s net sales in the quarter. Med Tech net sales were $24.5 million, a 29.7% increase from the prior-year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform. Growth was driven by Auryon sales during the quarter of $10.1 million, which increased 60.6%, and NanoKnife sales of $5.5 million, which increased 49.5% compared to the second quarter of fiscal 2022. NanoKnife disposable sales were $4.2 million, which increased 45.4% compared to the second quarter of fiscal 2022. Med Device net sales were $60.9 million, an increase of 2.6% compared to the prior-year period. U.S. net sales in the second quarter of fiscal 2023 were $71.6 million, an increase of 9.6% from $65.4 million a year ago”